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Background and Objectives
High-dose chemotherapy with allogeneic stem cell transplantation (SCT) has proven
to be a successful treatment for low-grade lymphoma (LGL), but is associated with
considerable transplant-related mortality (TRM). In an effort to reduce toxic mortality
while maintaining the graft-versus-leukemia effect, allogeneic SCT has been com-
bined with a reduced-intensity conditioning (RIC) regimen. The aim of this study was
to determine the outcome of patients with LGL treated with RIC allogeneic SCT.
Design and Methods
This retrospective multicenter study included 73 patients with relapsed or refractory
LGL allografted after a RIC regimen between 1998 and 2005 whose data were record-
ed in a French registry. 
Results
Patients received a median of three lines of therapy prior to RIC allogeneic SCT. The
most widely used conditioning regimens were fludarabine + busulfan + antithymocyte
globulin (n=43) and fludarabine + total body irradiation (n=21). Prior to allografting,
patients were in complete response (CR; n=21), partial response (PR; n=33) or had
chemoresistant disease (n=19). The median follow-up was 37 months (range, 16 to
77 months). In patients in CR, PR and chemoresistant disease, the 3-year overall sur-
vival rates were 66%, 64% and 32%, respectively, while the 3-year event-free survival
rates were 66%, 52% and 32%, respectively. The 3-year cumulative incidences of TRM
were 32%, 28% and 63%, respectively. The incidence of relapse was 9.6%.
Interpretation and Conclusions
Although associated with significant TRM, RIC allogeneic SCT in advanced
chemosensitive disease leads to long-term survival.    
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ABSTRACT
Low-grade lymphomas (LGL) are chemosensitiveneoplasms characterized by a relentless successionof remissions and relapses when treated with con-
ventional chemotherapy. The successive periods of remis-
sion are of shorter duration and patients invariably die of
their disease. Data from three randomized studies pro-
vide no evidence that high-dose chemotherapy (HDT)
with autologous stem cell transplantation (SCT) per-
formed in first remission improves the survival.1,2,3 The sit-
uation seems to be different in patients with relapsed dis-
ease as HDT with autologous SCT improved both
relapse-free and overall survival rates when compared to
conventional chemotherapy in a randomized trial.4
However, even in this trial, only half of the patients
achieved prolonged lymphoma-free survival after HDT
with autologous SCT. 
As a consequence of these findings, HDT with allo-
geneic SCT has been investigated as an additional ther-
apeutic option in younger patients. The efficacy of this
strategy is enhanced by the supportive presence of a
graft-versus-lymphoma (GVL) effect in chronic lympho-
proliferative diseases.5 Van Besien et al.6 reported rates of
3-year disease-free survival (DFS), overall survival (OS)
and incidence of relapse of 49%, 49% and 16%, respec-
tively, after allogeneic SCT with a myeloablative condi-
tioning regimen. They also documented a transplant-
related mortality (TRM) rate of 40% which was
explained in part by the advanced state of the disease in
the patients in their series. These results were updated
in a study that reported rates of 3-year DFS, OS, inci-
dence of relapse and TRM of 48%, 54%, 21% and 28%,
respectively.7 Other studies with myeloablative condi-
tioning regimens have reported comparable rates of
TRM.8-11 In an effort to reduce toxic mortality while still
exploiting the benefits of the GVL effect, recent studies
have combined allogeneic SCT with a reduced-intensity
conditioning (RIC) regimen. However, it is difficult to
draw conclusions from these reports as they are some-
what limited in scope by either small population sam-
ple,12 short follow-up,13 or heterogeneity in the disease
histologies.14 We, therefore, conducted a retrospective
multicenter study of the outcome of RIC-allogeneic SCT
in 73 patients with LGL whose data were recorded in
the registry of the Société Française de Greffe de Moelle
Osseuse et de Thérapie Cellulaire (SFGM-TC).
Design and Methods
Selection of patients
The selection criteria included adults patients with LGL
treated with a RIC regimen followed by allogeneic SCT
performed between January 1998 and June 2005. Patients
with transformed LGL, chronic lymphocytic leukemia or
mantle cell lymphoma were excluded. Information con-
cerning donors, recipients, graft harvesting and follow-up
procedures were collected by transplant centers using
prospectively designed forms. Seventy three patients
from 19 transplant centers were identified and included in
the present study. Retrospective diagnostic slide reviews
were not performed and molecular biology data were
unavailable. Information about performance status,
chimerism evolution and donor lymphocyte infusions
were also unavailable for the majority of patients.  
Evaluation of response
Response was evaluated in accordance with the stan-
dardized response criteria for non-Hodgkin’s lymphoma
as reported by Cheson et al.15 Complete response (CR)
was defined as the complete disappearance of all
detectable clinical, pathologic (i.e. bone marrow), and
radiographic evidence of disease, all disease-related
symptoms as well as the normalization of all biochemical
abnormalities. Partial response (PR) was defined as ≥50%
decrease of all measurable lesions. Stable disease (SD)
was defined as no response or a response < 50%.
Progressive disease (PD) was defined as at least a 50%
increase of any measurable lesion or appearance of any
new lesion during or at the end of therapy. Relapse was
defined as appearance of any new lesion in patients who
had achieved a CR.  
Patients’ general and transplant-related
characteristics 
The patients’ characteristics are summarized in Table 1.
A median number of 6×106 CD34+ cells/kg (range, 1.3 to
21.8×106) were injected (peripheral blood stem cells:
7.3×106 CD34+ cells/kg; range, 1.4 to 21.8×106 and bone
marrow stem cells: 2.8×106 CD34+ cells/kg; range, 1.3 to
5.5×106). Engraftment failed in two patients who died 2
months after transplantation from disseminated fungal
infection and multi-organ failure. Median times to reach
0.5×109 neutrophils/L, 20×109 platelets/L and 50×109
platelets/L were 14 days (range, 6 to 33 days), 10 days
(range, 0 to 232 days) and 14 days (range, 9 to 236 days),
respectively. The two most widely used conditioning reg-
imens were fludarabine + busulfan + antithymocyte glob-
ulin (ATG) [fludarabine 30 mg/m2 per day (days -4, -3, -2,
-1) with oral busulfan 0.5 mg/kg x 4 per day (days -4, -3,
-2, -1) with rabbit ATG 2.5 mg/kg/day (days -4, -3] and
fludarabine + total body irradiation (TBI) [fludarabine 30
mg/m2 per day (days -4, -3, -2) with 2 Gy of TBI on day
0]. Graft-versus-host disease (GvHD) prophylaxis consist-
ed of cyclosporine A (CsA) alone (5 to 6.25 mg/kg given
orally twice a day) or CsA + mycophenolate mofetil
(MMF, 15mg/kg per day given orally twice or three times
a day) or CsA + methotrexate on day +1 (15 mg/m2), +3
(10 mg/m2), and +6 (10 mg/m2). Intravenous formulations
of CsA and MMF were administered to patients who
were not able to tolerate oral medications. The multicen-
ter nature of this study precludes the identification of a
single pattern for tapering GvHD prophylaxis in patients
not developing acute GvHD. 
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Statistical analysis        
Univariate analysis was utilized to assess whether
overall survival (OS), event-free survival (EFS) and TRM
were affected by the number of lines of therapy
received prior to allogeneic SCT or by the status of the
disease at the time of the transplant. Prior lines of ther-
apy were distributed as follows: one line (n=4, group 1),
two lines (n=30, group 2), three lines (n=20, group 3),
more than three lines (n=19, group 4). Groups 1 and 2
were combined because of the small number of patients
in group 1. Comparisons were conducted between the
three resultant groups: groups 1+2, group 3 and group 4.
A similar reasoning was applied to the disease status
which was distributed as follows: CR (n=21, group 1),
PR (n=33, group 2), SD (n=7, group 3), PD (n=12, group
4). In this instance, the number of patients in group 3
was small. Groups 3 and 4 were therefore combined
and comparisons were conducted between group 1,
group 2 and groups 3+4 the latter of which was also the
group of patients with chemoresistant disease.  
Overall survival was calculated from the date of trans-
plantation to either the date of death from any cause or
last follow-up. Event-free survival was calculated from
the date of transplantation to the date of relapse, pro-
gression, death from any cause or last follow-up.
Transplant-related mortality included all causes of death
other than disease relapse or progression occurring at
any time after transplantation. Survival estimates were
determined using the Kaplan and Meier method and
compared by the log-rank test (univariate analysis) or by
the Cox proportional hazards regression model (multi-
variate analysis). In the univariate analyses, GvHD was
studied as a time-dependent covariate in a Cox model.
Probabilities of GvHD, relapse and TRM were calculat-
ed by using cumulative incidence functions to allow for
competing risks. Relapse and death without relapse
were considered as competing risks for TRM and
relapse, respectively. Relapse and death were consid-
ered as competing risks for GvHD. A Cox regression
model was used to compare TRM and relapse hazards.
Variables included in the univariate analyses were age (≥
vs <50 years), histology (follicular vs non-follicular),
number of prior lines of therapy, chemoresistance,
severe acute GvHD (grades III + IV), chronic GvHD,
donor (related vs unrelated), conditioning regimen (ATG
vs no ATG and fludarabine + TBI vs others), prior autol-
ogous SCT, and source of stem cells (peripheral blood vs
bone marrow). Variables showing a p value <0.2 in the
univariate analyses were entered in a multiple Cox
model and sequentially removed from the model if they
were not significantly associated with the outcome at
the 0.05 level.   
Results
Patients’ characteristics
The median age of the population was 51 years (range,
33 to 66 years). Sixty-two percent of patients were male.
The predominant histology was follicular (n=61). Other
histologies were lymphoplasmacytoid (n=5), lympho-
cytic (n=4), and marginal zone B cell (n=3). Seventy-one
patients were transplanted because of relapsed disease.
Among these patients, 21 were in CR at the time of allo-
geneic SCT, while 33 were in PR, 6 had SD and 11 had
PD. Two patients never achieved a complete or partial
response during the course of their disease and were
thus considered as having primary refractory at the time
of alloSCT (one with SD, one with PD).      
RIC allogeneic SCT in low-grade lymphoma
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Table 1. General and transplant-related characteristics of the
study population (n=73).  
No. %
Time from diagnosis to alloSCT, months
Median 46
Range 6-284
Prior lines of therapy
1 4 5.5
2 30 41.1
3 20 27.4
>3 19 26
Prior autoSCT 
Yes 25 34.2
No 48 63.8
Disease status at alloSCT
Complete response 21 28.8
Partial response 33 45.2
Stable disease 7 9.6
Progressive disease 12 16.4
Conditioning regimen
Fluda + Bus + ATG 43 59
Fluda + TBI 21 28.7
Fluda + EDX 3 4
EDX + ATG 2 2.7
Fluda + Ida + Ara-C 1 1.4
Fluda + MoAbsCD20 1 1.4
Fluda + Melphalan 1 1.4
Fluda + BEAM 1 1.4
Source of stem cells
Peripheral blood 59 80.8
Bone marrow 14 19.2
Donor
Matched related 63 86.3
Matched unrelated 7 9.6
Mismatched related 1 1.4
Mismatched unrelated 2 2.7
GvHD prophylaxis
Cyclosporine A alone 32 43.8
Cyclosporine A + MMF 25 34.2
Cyclosporine A + Methotrexate 16 22
AlloSCT: allogeneic stem cell transplantation; autoSCT: autologous stem cell
transplantation; Fluda: fludarabine; Bus: busulfan; ATG: antithymocyte globulin;
TBI: total body irradiation; EDX: endoxan; Ida: idarubicin; MoAbsCD20, anti-
CD20 monoclonal antibody; BEAM, BCNU + etoposide + Ara-C + melphalan;
GvHD: graft-versus-host disease; MMF: mycophenolate mofetil; Metho:
methotrexate. 
Survival  
The median follow-up of surviving patients was 37
months (range, 12 to 77 months). Three-year OS and EF
rates were 56% (95% CI, 45% to 69%) and 51% (95%
CI, 40% to 64%), respectively (Figure 1). Thirty two
patients died by a median time of 6 months after allo-
geneic SCT (range, 1 to 58 months). The causes of death
are presented in Table 2. The number of lines of thera-
py prior to allogeneic SCT did not affect either OS or
EFS. However, patients with chemoresistant disease
had significantly worse OS and EFS than patients with
chemosensitive disease (CR or PR). As shown in Figure
2, the 3-year OS rates in CR, PR and chemoresistant
patients were 66%, 64% and 32%, respectively
(p=0.001) while the 3-year EFS rates in the same
patients were 66%, 52% and 32%, respectively
(p=0.003). Univariate analysis determined that OS was
also adversely affected by unrelated donor and the
development of severe acute GvHD, while EFS was also
adversely affected by severe acute GvHD and condi-
tioning regimen other than Fludarabine+TBI.
Multivariate analysis (Table 3) indicated that both OS
and EFS rates were adversely affected by chemoresis-
tance and severe acute GvHD.
Transplant-related mortality 
As shown in Figure 3, the 3-year TRM was 40% (95%
CI, 28% to 51%). TRM rates at 100 days, 1 year and 2
years were 9%, 32% and 37%, respectively. Twenty-nine
patients died of causes other than relapse at a median time
of 5 months after allogeneic SCT (range, 1 to 34 months).
The causes of TRM before and after day 100 are detailed in
Table 2. The number of lines of therapy prior to SCT did
not affect TRM. As shown in Figure 4, patients with
chemoresistant disease had a significantly higher 3-year
TRM (63%) than patients who achieved CR (32%) or PR
(28%) (p=0.005). Univariate analysis indicated that severe
acute GvHD and grafts from unrelated donors were also
predictors of higher TRM. Indeed, the nine patients affect-
ed by grade III (n=4) or IV (n=5) acute GvHD died of caus-
es other than relapse (refractory GvHD: n=6, bacterial
infection: n=2, hemorrhage: n=1) at a median time of 5
months after allogeneic SCT. Multivariate analysis (Table
3) indicated that chemoresistance and severe acute GvHD
adversely affected TRM. The year of transplant was not
found to be significantly associated with TRM (data not
shown). Table 4 shows that three or more lines of therapy
were administered prior to allogeneic SCT to 74% of
patients with chemoresistant disease and to 46% of
patients with chemosensitive disease (p=0.04). An unrelat-
ed donor was used in 32% and 6% of these same patients,
respectively (p=0.003).       
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Figure 1. Overall survival and event-free survival of the study pop-
ulation (n=73). Figure 2. Overall survival and event-free survival according to the sta-
tus of disease at the time of allogeneic stem cell transplantation. CR:
complete response group (n=21): PR: partial response group (n=33);
refractory: stable + progressive disease group (n=19). 
Table 2. Causes of death in the study population.
Less than 100 days* More than 100 days*
(n=10) (n=19)
Lymphoma progression n=3
Transplant-related causes n=29
Multi-organ failure 2 1
Acute GvHD 4 2
Chronic GvHD / 1
Bacterial infection 1 4
Fungal infection 1 2
Hemorrhage 1 3
Encephalitis 1 1
Interstitial pneumonitis 0 2
Hepatitis 0 1
Unknown 0 2
*Days post-transplantation; GvHD: graft-versus-host disease.
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Graft-versus-host disease
Acute GvHD occurred in 34 patients (grade I, n=9;
grade II, n=16; grade III, n=4; grade IV, n=5) at a median
time of 30 days after transplantation (range, 5 to 135
days). The incidences of grades II to IV and grades III +
IV acute GvHD were 34% and 12%, respectively.
Chronic GvHD occurred in 31 patients (limited, n=16;
extensive, n=15) at a median time of 6 months after
transplantation (range, 1 to 20 months). At 20 months,
the cumulative incidences of chronic GvHD and of
extensive chronic GvHD were 43% (95% CI, 31% to
54%) and 20% (95% CI, 11% to 30%), respectively.
Both incidences remained constant at 5 years.  
Relapse or progression
The 3-year cumulative incidence of relapse or pro-
gression was 9.6% (95% CI, 2.8% to 16.5%; Figure 3).
Five patients relapsed at 10, 10, 16, 38, and 43 months.
Four patients progressed at 3, 4, 4, and 9 months.
Univariate analysis was unable to identify a predictor of
lower risk of relapse.    
Discussion
This study reports the outcome of 73 patients with
relapsed or refractory LGL with a median follow-up of
37 months after RIC allogeneic SCT. The transplants
were performed in 19 transplant centers in France
between 1998 and 2005. This is the largest study with
the longest follow-up period conducted in patients
with LGL treated with RIC-allogeneic SCT. Fifty-nine
percent of the patients received the fludarabine +
busulfan + ATG conditioning regimen as reported by
Slavin et al.16 The use of this regimen was not linked to
the use of unrelated donors as only 12% of patients
received grafts from such a donor. Most patients were
heavily pre-treated and one quarter had chemoresis-
tant disease at transplantation, indicating a population
Table 3. Results of multivariate analysis.
Outcome Variable HR CI (95%) p value
OS chemoresistance 2.9 1.3 to 6.5 0.009
OS acute GvHD 5.8 2.4 to 13.9 < 0.001
EFS chemoresistance 2.6 1.3 to 5.5 0.009
EFS acute GvHD 4.6 2 to 10.7 < 0.001
TRM chemoresistance 2.9 1.3 to 7 0.01
TRM acute GvHD 6.9 2.7 to 17.8 < 0.001
OS: overall survival; EFS: event-free survival; TRM: transplant-related mortality;
HR: hazards ratio; CI: confidence interval. Only variables that were statistically
significant in the multivariate analysis are given. For OS and EFS, the variables
included in the multivariate analysis were chemoresistance, acute GvHD
(grades III + IV), chronic GvHD, fludarabine + TBI conditioning regimen,
and unrelated donor. For TRM, the variables included in the multivariate
analysis were chemoresistance, acute GvHD (grades III + IV), chronic GvHD,
unrelated donor, fludarabine + TBI conditioning regimen and prior autologous
stem cell transplantation. 
Figure 3. Cumulative incidences of transplant-related mortality
(TRM) and relapse of the study population (n=73).   
Figure 4. Transplant-related mortality according to the status of
disease at the time of allogeneic stem cell transplantation.
CR: complete response group (n=21); PR: partial response group
(n=33); refractory: stable + progressive disease group (n=19). 
Table 4. Comparison of patients with chemosensitive disease
(CR+PR) and patients with chemoresistant disease (SD+PD).
Chemosensitive Chemoresistant p*
(n=54) (n=19)
Median age (range) 51** (37-61) 51 (33-66) 0.4
Transplant period 0.2
1998-2001 23 (43%) 10 (53%)
2002-2005 31 (57%) 9 (47%)
Previous lines of therapy 0.04
< 3 29 (54%) 5 (26%)
≥3 25 (46%) 14 (74%)
Unrelated donor 3 (6%) 6 (32%) 0.003
CR: complete response; PR: partial response; SD: stable disease;
PD: progressive disease. *χ2 test, ** years. 
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at a high risk of relapse. In these conditions, we report
3-year lymphoma-free survival rates of 66%, 52% and
32% in patients with CR, PR and chemoresistant dis-
ease, respectively, with a low incidence of relapse. The
incidence of TRM in patients with chemosensitive dis-
ease (CR+PR) was half that in patients with chemore-
sistant disease. The overall incidence of grades II-IV
acute GvHD was 34% and is most likely explained by
the advanced median age of our patients (51 years).
Moreover, grades II-IV acute GvHD occurred at a
median time of 35 days post-transplantation which is
after the protective effect of ATG had abated.
Multivariate analysis indicated that OS, EFS and TRM
rates were all adversely affected by chemoresistance
and severe acute GvHD. 
The first reports on the use of allogeneic SCT after  a
myeloablative conditioning regimen in patients with
relapsed or refractory LGL showed that prolonged
lymphoma-free survival could be obtained in about
half of patients, with TRM ranging from 20 to 30%.7-11
Afterwards, RIC-allogeneic SCT, which is used in
patients on average 10 years older, was evaluated as an
alternative strategy to reduce the toxicity while spar-
ing the GVL effect. The results of the present study
and of four others on RIC-allogeneic SCT in patients
with relapsed or refractory LGL are presented in Table
5.12-14,17 Patients had comparable median ages ranging
from 46 to 51 years. They were all heavily pre-treated
with a median of two to three lines of previous thera-
py. One third of the patients had undergone a previous
autologous SCT, except in Khouri’s series. Although
the two studies by Robinsonet al.13 and Maris et al.17
differ from our study, with shorter follow-up periods
and higher incidences of relapse, they also reported
similar survivals and incidences of TRM. These two
studies, combined with our report, indicate that 2 to 3-
year lymphoma-free survival rates of 51-54% and
TRM of 31-40% can be expected after RIC-allogeneic
SCT in patients with relapsed or refractory LGL. It
remains unclear from these results whether the RIC
regimen substantially reduces the TRM when com-
pared to the myeloablative conditioning regimen.7-10
These findings suggest instead that TRM is delayed
rather than truly decreased as indicated in Table 5 by
the higher incidences of TRM at 2 years than at 100
days. Such a pattern of delayed TRM is not disease-
specific since it has also been reported in high-grade
lymphoma13 and Hodgkin’s disease.18 Collectively,
these data highlight the importance of long follow-up
periods for the analysis of TRM after RIC-allogeneic
SCT and also underline the need for comparisons
between RIC and myeloablative conditioning regi-
mens.  
Better results were reported by Khouri et al.12 in a
study with a short follow-up and a smaller number of
patients. The first 11 patients received fludarabine and
cyclophosphamide as a conditioning regimen while
the nine subsequent patients received the same regi-
men plus rituximab at a dose of 375 mg/m2 IV on day
– 6 before transplantation and 1000 mg/m2 IV on days
1, 8 and 15 after transplantation. A recently published
abstract updated these findings in a study consisting of
47 patients with a median follow-up of 34 months.
The updated results were a 3-year OS and EFS of 88%
Table 5. Results of studies on allogeneic stem cell transplantation after a reduced-intensity conditioning regimen in patients with low-
grade lymphoma.  
Khouri IF Robinson SP Morris E Maris MB Present 
et al.,12 2001 et al.,13 2002 et al.,14 2004 et al.,17 2005 study
Number of  patients 20 52 41 45 73
Median age (years) 51 46 48 54 51
Median follow-up (months) 21 9 36 24 37
Prior lines of therapy 2 3 3 NA 3
Prior autoSCT 5% 29% 37% 33% 34%
Chemosens/chemores 90%/10% 85%/10%* 97%/3% 63%/24%** 74%/26%
Overall survival 84% (at 2 years) 65% (at 2 years) 73% (at 3 years) 58% (at 2 years) 56% (at 3 years)
Event-free survival 84% (at 2 years) 54% (at 2 years) 65% (at 3 years) 51% (at 2 years) 51% (at 3 years)
Relapse/progression 0% 21% (at 2 years) 44% (at 3 years) 15% (at 2 years) 9.6% (at 3 years)
100-day TRM 10% 11.5% 2% NA 9%
2-year TRM NA 30.9% 11% 34% 37%
NA: not available; autoSCT, autologous stem cell transplantation; chemosens: chemosensitive disease; chemores: chemoresistant disease; TRM: transplant-related
mortality. * untested relapse: 5%; **untested relapse: 13%.
and 85%, respectively.19 Using a different strategy with
in vivo T-cell depletion, Morris et al. reported their
experience with a conditioning regimen comprising
fludarabine, melphalan and alemtuzumab.14 In this
study, patients with a relapse, progressive disease,
minimal residual disease or mixed chimerism at 6
months were given donor lymphocyte infusions. All
patients but one had chemosensitive disease at trans-
plantation. In our study, patients with chemosensitive
disease (CR+PR) had 3-year OS, EFS, TRM and inci-
dence of relapse of 65%, 58%, 31% and 11%, respec-
tively. These results indicate that comparable OS and
EFS rates can be obtained in patients with a chemosen-
sitive disease whether or not a T-cell depletion strate-
gy is adopted. However, Morris et al. reported a high-
er incidence of relapse and a lower TRM compared to
our study. Collectively, these data suggest that allo-
geneic SCT after a RIC regimen including alemtuzum-
ab in patients with chemosensitive LGL is associated
with a reduced TRM, a higher risk of relapse and sim-
ilar survival rates when compared to those after allo-
geneic SCT with a T-cell replete RIC regimen. 
There is now evidence from randomized studies that
rituximab combined with chemotherapy improves the
outcome of patients with follicular lymphoma.20,21
Moreover, several studies have reported that mainte-
nance treatment with rituximab improves response
duration and survival.22-25 These interesting results raise
the possibility that rituximab may also improve the
outcome of RIC-allogeneic SCT in patients with follic-
ular lymphoma. Khouri et al. adopted such a transplant
strategy with the supposition that the administration
of rituximab in the conditioning regimen and after
RIC-allogeneic SCT might improve patients’ outcome
by affording better control of the disease during the
period early after transplantation prior to the develop-
ment of any GVL effect. Although the preliminary
results are promising,12,19 better control of the disease
with rituximab in this setting remains hypothetical.
Kamble et al.26 recently reported that refractory acute
GvHD improved in three patients after treatment with
rituximab, suggesting a potential role for B cells in the
pathogenesis of acute GvHD. Although the results still
need to be confirmed in larger trials, this latter report
raises the possibility that rituximab used in the condi-
tioning regimen or administered after allogeneic SCT
may act to improve patients’ outcome via better pro-
phylaxis of severe acute GvHD which was found to
adversely affect TRM in our study.  
Our study shows that patients with chemoresistant
LGL have a poor outcome after RIC allogeneic SCT
with a high incidence of TRM, possibly attributable to
the high number of previous lines of therapy and the
use of the grafts from unrelated donors for one third of
these patients. This finding strongly questions the valid-
ity of performing an allogeneic SCT procedure using a
RIC regimen in patients with chemoresistant disease.
These patients would more likely benefit from the
administration of investigational therapies aimed at
controlling the disease before reconsidering the use of
allogeneic SCT. We also report a better outcome when
the disease is chemosensitive, with patients in CR or PR
having 3-year lymphoma-free survival rates of 66% and
52%, respectively. Although the design of our study
prohibits speculation about a better timing of RIC allo-
geneic SCT in second or subsequent relapse, the poten-
tial impact of this issue on disease outcome warrants
further examination through appropriate prospective
trials. We conclude that RIC allogeneic SCT is a valuable
therapeutic option in patients with chemosensitive
relapsed LGL even after multiple lines of therapy.    
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